AMBITION 3: A research study investigating how well zenagamtide at higher dose levels lowers blood sugar and body weight compared to semaglutide in people with type 2 diabetes treated with metformin, SGLT2i, or both

Brief summary (registry, in English)

To confirm non-inferiority of [CCI] zenagamtide versus [CCI] semaglutide on change in glycated haemoglobin (HbA1c) in participants with T2D not in adequate glycaemic control on stable dose of metformin, SGLT2i, or both

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 595
• 117 sites in 13 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled on metformin, an SGLT2 inhibitor, or both.

Age

18 years or older

Sex

All sexes can join (sex assigned at birth, all gender identities).

Disease stage

Type 2 diabetes diagnosed at least 180 days before screening, with blood sugar (HbA1c) not well controlled.

Earlier treatment

Must be on a stable daily dose of metformin, an SGLT2 inhibitor, or both. Must not have had GLP-1 based treatments or amylin analogues, or other diabetes or obesity medicines.

Biomarker or test result

HbA1c level measured by a central laboratory at screening (the exact range is not shown in the record).

Main reasons for not taking part

• Pregnant, breast-feeding, planning pregnancy, or able to become pregnant and not using adequate contraception
• Heart attack, stroke, mini-stroke or hospital stay for unstable angina within 60 days before screening
• Chronic heart failure of NYHA Class IV
• Planned heart, neck or leg artery revascularisation
• Diabetic eye disease treated within 180 days before screening, or expected to need treatment within 180 days after

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (117)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details